Skip to main content

Latest News

DECISION TO RECOMMEND MAVENCLAD®

20th August 2018

The Pharmaceutical Benefits Advisory Committee (PBAC) announced the recommendation for listing on the Pharmaceutical Benefits Scheme (PBS) of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS), subject to final approval by the Federal Health Minister.

Read More
article.heroMedia.text

LOCAL BIOMARKER RESEARCH A KEY PART OF MSWA’S RECORD $3 MILLION INVESTMENT

14th August 2018

For the thousands of Western Australians living with multiple sclerosis (MS) new treatments offer hope and relief. But for clinicians it’s often challenging to know if a particular treatment is working.

Read More
article.heroMedia.text

World MS Day, bringing us closer

30th May 2018

Fatigue and blurred vision were the first signs for Chloe Baker that something wasn’t right. In 2017, the 31-year-old moved home from New Zealand to be with her family and focus on her health. An eye test led to an MRI, and then a diagnosis of multiple sclerosis (MS).

Read More
article.heroMedia.text

SUBSEQUENT DECISION NOT TO RECOMMEND MAVENCLAD®

23rd April 2018

The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

Read More
article.heroMedia.text

Show your support

With your support, MSWA are delivering real things to real people living with neurological conditions in Western Australia.

It is easy to show your support. You can buy a raffle ticket, a lottery ticket, even an entertainment book, or simply donate.


Find out more.